A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: Analyses from a phase 2 study in patients treated with ixekizumab

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 5, 2016, Pages 864-865

  Edson Heredia, E ^a   Banerjee, S ^a   Zhu, B ^a   Maeda Chubachi, T ^a   Cameron, G S ^a   Shen, W ^a   Heffernan, M P ^a   Gordon, K B ^b   Leonardi, C L ^c  

^a ELI LILLY AND COMPANY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IXEKIZUMAB; PLACEBO; MONOCLONAL ANTIBODY;

DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; HUMAN; ITCH VISUAL ANALOG SCALE; LETTER; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; PSORIASIS; TREATMENT OUTCOME;

EID: 84924678707     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13032     Document Type: Letter

References (8)

1. European Medicines Agency Committee for Medicinal Products for Human Use. 2004. Guideline on Clinical Investigation of Medicinal Products for the Treatment of Psoriasis. CHMP/EWP/2454/02 corr. [WWW document] URL http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003329.pdf (last accessed 17 January 2014).
2. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and Psoriatic arthritis. J Am Acad Dermatol 2008; 58: 826-850.
3. Feldman SR, Kreuger GG,. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): ii65-ii68.
4. Revicki DA, Willian MK, Menter A, et al,. Relationship between clinical response to therapy and health-related quality of life in patients with moderate to severe plaque psoriasis. Dermatology 2008; 216: 260-270.
5. Shikiar R, Bresnahan BW, Stone SP, et al,. Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53.
6. Feldman SR, Menter A, Koo JY,. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150: 317-326.
7. Shikiar R, Willian MK, Okun MM, et al,. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4: 71.
8. Leonardi C, Matheson R, Zachariae C, et al,. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-1199.